Core Viewpoint - NurExone Biologic Inc. announced preclinical results showing that 100% of small animals treated with a higher dose of ExoPTEN regained motor function after spinal cord injury, indicating significant therapeutic potential for the treatment of such injuries [4][5][6]. Group 1: Study Results - The study utilized the CatWalk XT system to assess the effects of ExoPTEN on animal locomotion, revealing that all animals in the high-dose group exhibited measurable gait recovery, while only one animal in the untreated group showed minimal improvement [5][6]. - A dose-dependent effect was observed, with 100% of animals in the high-dose group regaining walking ability in both hind limbs, compared to 50% in the medium-dose group and only 1 out of 6 in the untreated control group [6]. - Gait analysis demonstrated improvements in various parameters, including larger hind paw print areas, greater maximum contact area, wider base of support, and extended duration of paw contact with the walkway, reflecting enhanced balance and coordination [6][7]. Group 2: Future Plans and Development - The company plans to initiate additional studies to explore alternative dosing regimens and optimize ExoPTEN's manufacturing processes and analytical methods, aiming to refine the drug's therapeutic profile [7][9]. - NurExone is preparing for regulatory submissions and aims to launch first-in-human clinical trials, focusing on developing treatments for nervous system injuries [9][10]. - The company has established Exo-Top Inc., a U.S. subsidiary, to support its North American growth strategy and enhance its market presence [10].